Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOC | P08134 | 2/20 | 0.40 |
| ▸ | RHOA | P61586 | 2/20 | 0.40 |
| ▸ | UBE2M | P61081 | 1/20 | 0.40 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 6/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.36 |
| ▸ | TEAD1 | P28347 | 6/20 | 0.35 |
| ▸ | TEC | P42680 | 2/20 | 0.34 |
| ▸ | TXK | P42681 | 2/20 | 0.34 |
| ▸ | BMX | P51813 | 2/20 | 0.34 |
| ▸ | ITK | Q08881 | 2/20 | 0.34 |
| ▸ | IL1B | P01584 | 2/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24781071 | 0.83 | TEAD1 (0.45) | UBE2MDCUN1D1TEAD1 | |
| SCHEMBL21958158 | 0.79 | TEAD1 (0.55) | RHOCRHOADCUN1D1BTKTEAD1 | |
| SCHEMBL21958755 | 0.79 | TEAD1 (0.55) | RHOCRHOADCUN1D1BTKTEAD1 | |
| SCHEMBL24780794 | 0.75 | TEAD1 (0.41) | UBE2MDCUN1D1TEAD1IL1B | |
| SCHEMBL21856326 | 0.73 | RHOC (0.42) | RHOCRHOAUBE2MDCUN1D1BTK | |
| SCHEMBL21958183 | 0.69 | TEAD1 (0.60) | RHOCRHOADCUN1D1BTKTEAD1 | |
| SCHEMBL21958157 | 0.69 | TEAD1 (0.60) | RHOCRHOADCUN1D1BTKTEAD1 | |
| SCHEMBL25785369 | 0.65 | TEAD1 (0.55) | RHOCRHOADCUN1D1BTKTEAD1 | |
| SCHEMBL21856317 | 0.65 | IDH2 (0.43) | UBE2MDCUN1D1TEAD1 | |
| SCHEMBL21958156 | 0.63 | TEAD1 (0.53) | BTKTEAD1ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | RHOC 4316/4885RHOA 3287/4885UBE2M 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.